GGHC
SGTX

Gilder Gagnon Howe & Co’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,515
Closed -$909K – 445
2021
Q2 		$909K Sell
6,515
-43,809
-87% -$7.7M ﹤0.01% 333
2021
Q1 		$14.6M Sell
50,324
-617
-1% -$245K 0.08% 176
2020
Q4 		$31.8M Buy
+50,941
New +$23.1M 0.16% 126

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Gilder Gagnon Howe & Co's SGTX Position: Q3 2021 in Review

Gilder Gagnon Howe & Co sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2021, closing a stake of 6,515 shares — an estimated $909K sold.

Gilder Gagnon Howe & Co first reported a position in SGTX in Q4 2020 and held it in 3 quarters. The position peaked at $31.8M in Q4 2020. 45 funds tracked by Wall St. Rank hold SGTX as of Q3 2021.

  • Gilder Gagnon Howe & Co reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 6,515 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $909K.
  • Gilder Gagnon Howe & Co first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Gilder Gagnon Howe & Co's Sigilon Therapeutics, Inc. Common Stock position peaked at $31.8M in Q4 2020.
  • 45 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2021, filed 15 Nov 2021.